Ketorolac Tablets: Creatinine Thresholds and Dosing Frequency
Oral ketorolac should only be used as continuation therapy after IV/IM ketorolac, not as initial treatment, and is contraindicated in patients with advanced renal impairment (serum creatinine ≥5 mg/dL) or creatinine clearance <30 mL/min. 1
Contraindications Based on Renal Function
Absolute contraindications for ketorolac tablets include:
- Serum creatinine ≥5 mg/dL 1
- Advanced renal impairment or patients at risk for renal failure due to volume depletion 1
- Creatinine clearance <30 mL/min (based on NSAID guidance for this class) 2
The FDA label explicitly states that ketorolac should be avoided in patients with advanced renal impairment, and the KDOQI guidelines recommend avoiding NSAIDs entirely when GFR <30 mL/min/1.73 m² 2. For patients with GFR 30-60 mL/min/1.73 m², prolonged NSAID therapy is not recommended, though short-term use may be considered with extreme caution 2.
Dosing Frequency and Duration
Standard dosing regimen:
- Initial dose: 20 mg orally once (for patients age 17-64 years) or 10 mg once (for patients ≥65 years, renally impaired, or weight <50 kg) 1
- Maintenance: 10 mg every 4-6 hours as needed 1
- Maximum daily dose: 40 mg/day 1
- Maximum treatment duration: Combined IV/IM and oral therapy must not exceed 5 days total 1
The dosing interval should never be shortened below 4-6 hours, and the minimum effective dose should always be used 1.
Special Populations Requiring Dose Reduction
Patients requiring the lower 10 mg initial dose include: 1
- Age ≥65 years
- Body weight <50 kg (110 lbs)
- Any degree of renal impairment (even mild)
These patients receive 10 mg as the initial oral dose, then 10 mg every 4-6 hours, not exceeding 40 mg/day 1.
Critical Monitoring and Drug Interactions
Renal function must be monitored closely because:
- NSAIDs like ketorolac can reduce the natriuretic effect of diuretics and precipitate renal failure 1
- Concomitant use with ACE inhibitors or ARBs increases risk of renal impairment, particularly in volume-depleted patients 1
- Probenecid is contraindicated with ketorolac as it increases ketorolac levels threefold and doubles the half-life 1
Patients should be observed for signs of renal failure during concomitant therapy with diuretics, and diuretic efficacy should be monitored 1. The AGA guidelines for cirrhosis patients emphasize that NSAIDs should be discontinued when AKI is diagnosed 2.
Common Pitfalls to Avoid
Do not use oral ketorolac as initial therapy – it is only FDA-approved as continuation after IV/IM dosing 1. The oral formulation should never be given as the first dose 1.
Do not exceed 5 days total duration – this includes the combined time on IV/IM plus oral formulations 1. Extended NSAID use in patients with any renal impairment significantly increases risk 2.
Do not overlook volume status – ketorolac combined with ACE inhibitors/ARBs poses particular risk in volume-depleted patients 1. Adequate hydration should be ensured before and during therapy 2.
Avoid in elderly with multiple risk factors – patients ≥65 years with concurrent diuretics, ACE inhibitors, or baseline creatinine elevation are at substantially higher risk for acute kidney injury 2.